99624-27-8

99624-27-8 structure

Name: Kazinol B
Chemical Name: Kazinol B
CAS Number: 99624-27-8
Molecular Formula: C₂₅H₂₈O₄
Molecular Weight: 392.487
Catalog: Natural product Flavonoids
Create Date: 2016-03-18 07:48:42
Modify Date: 2024-01-09 16:37:54
Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research[1][2].

Name	Kazinol B
Synonyms	(2S)-2',2'-Dimethyl-7'-(3-methyl-2-buten-1-yl)-3,4-dihydro-2H,2'H-2,6'-bichromene-7,8'-diol [2,6'-Bi-2H-1-benzopyran]-7,8'-diol, 3,4-dihydro-2',2'-dimethyl-7'-(3-methyl-2-buten-1-yl)-, (2S)-

Description	Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research[1][2].
Related Catalog	Signaling Pathways >> Epigenetics >> AMPK Signaling Pathways >> Immunology/Inflammation >> NO Synthase Signaling Pathways >> PI3K/Akt/mTOR >> Akt Signaling Pathways >> PI3K/Akt/mTOR >> AMPK Research Areas >> Metabolic Disease
Target	Akt AMPK
In Vitro	Kazinol B (2, 10 and 20 μM; 72 hours) shows no toxicity to adipocytes in 3T3-L1 cells[1]. Kazinol B (2-20 μM; 72 hours) dose-dependently increases lipid accumulation by 2.4-fold (at 20 μM) treatment as compared with MDI-treated cells[1]. Kazinol B (2-20 μM; 5 days) dose-dependently increases PPARγ and C/EBPα protein and mRNA levels in MDI-treated 3T3-L1 adipocytes. Kazinol B increases the mRNA level of adiponectin in a dose-dependent manner[1]. Kazinol B (2-20 μM; 24 hours) increases the retained 2ʹNBDG-fluorescence in cells in a dose-dependent manner in differentiated 3T3-L1 adipocytes and C2C12 myoblasts. Kazinol B dependently increases the MDI-stimulated GLUT4 mRNA level up to 4.7-fold as compared with MDI-only treated cells[1]. Kazinol B (10-20 μM; pre-treated for 1 h followed by 1 h insulin) dose-dependently increases insulin-dependent Akt phosphorylation. Kazinol B alone strongly induces Akt phosphorylation compared with untreated cells. Kazinol B also increased insulin-stimulated AMPK phosphorylation[1]. Kazinol B (6.25, 12.5, 25, 50 μM; 18 hours) dose-dependently reduces amounts of iNOS protein in macrophages (RAW 264.7 cells) activated by LPS (1 ug/mL)[2].
References	[1]. Hyejin Lee, et al. Kazinol B from Broussonetia kazinoki improves insulin sensitivity via Akt and AMPK activation in 3T3-L1 adipocytes. Fitoterapia. 2016 Jul;112:90-6. [2]. Jae-Ha Ryu, et al. Fitoterapia. 2003 Jun;74(4):350-4.Inhibition of nitric oxide production on LPS-activated macrophages by kazinol B from Broussonetia kazinoki.

Density	1.2±0.1 g/cm3
Boiling Point	556.6±50.0 °C at 760 mmHg
Molecular Formula	C₂₅H₂₈O₄
Molecular Weight	392.487
Flash Point	290.4±30.1 °C
Exact Mass	392.198761
PSA	58.92000
LogP	6.77
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.601

Hazard Codes	Xi

99624-27-8	104494-37-3
104494-34-0	104494-32-8
104494-33-9	105650-11-1
105708-64-3	161503-23-7
102363-24-6	124512-46-5
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	2171708-92-0
2138231-90-8	2137605-84-4
930439-75-1	1018584-77-4